INTRODUCTION {#sec1-1}
============

Stroke is a complex, multifactorial disease. It is one of the leading causes of disability and death. About 80% of all strokes are ischemic and have a polygenic basis. Advances in genetic epidemiology have revealed that some genetic variants increase the risk for IS. Evidence suggests that genetic variation in the rennin angiotensin-aldosterone system (RAAS) contributes to the risk of ischemic stroke. Among the various sequence variations in RAAS, the insertion/deletion (*I/D*) polymorphism in angiotensin I- converting enzyme (ACE) is the most extensively studied.

ACE is a dipeptidyl carboxylase that converts angiotensin I into the antinatriuretic vasoactive angiotensin II, an octapeptide involved in vasoconstriction, aldosterone production, and norepinephrine release from sympathetic nerve endings and inactivates bradykinin, a vasodilator and natriuretic substance. ACE is encoded by a 21-kb 26 exons gene located on chromosome 17 at q23. A deletion polymorphism in the ACE gene consists of the absence of a 287-bp Alu repetitive sequence in reverse orientation near the 3' end of intron 16. Mean ACE activity concentration in DD carriers are around twice those found in II carriers ([@ref1], [@ref2]).

The purpose of this study was: a) to report the distribution of ACE genotypes and alleles in patients with ischemic stroke (IS), b) to investigate the impact of ACE polymorphism on serum lipid and apolipoprotein concentrations, as well as on ACE activity and arterial blood pressure level.

MATERIALS AND METHODS {#sec1-2}
=====================

Blood samples were obtained from 65 unrelated subjects with acute IS (mean age 41). These were proven by computed tomography or magnetic resonance of the brain. Acute stroke patients were separated into two groups: one with large vessel disease (45 patients) and the other with small vessel disease (lacunar stroke) (20 patients). The age and BMI-matched control group consisted of 330 unrelated Serbian people. They did not show any signs of cerebrovascular disease from their health questionnaires and clinical examinations. Informed consent was obtained from each participant in the study; and all procedures were in accordance with the Helsinki Declaration.

DNA was extracted by Triton X-100 lysis, proteinase K digestion and phenol/chloroform extraction. The reaction pertaining to ACE was performed with 20 pmol of the sense strand-specific primer SA66, 7 pmol of the anti-sense strand-specific primer 167, and 1.5 pmol of another I allele sense strand specific primer ACE3, as previously described ([@ref3]). Amplification products pertaining to I/D polymorphism were separated by electrophoresis in 1.8 % (w/V) agarose gels. Alleles were identified according to their expected lengths. All gels were visualized and analyzed by GDS8000 gel documentation system (Ultra Violet Products Inc, Upland). ACE activity was determined in serum samples using commercial test (Trinity, Biotech). Lipid and apolipoprotein concentrations were determined by standard methods.

STATISTICAL ANALYSIS {#sec1-3}
====================

Results are presented as mean ± S.D. for continuous normally distributed variables, and as percent for categorical data. Comparisons between normally distributed continuous variables were performed by the Student's t-test and ANOVA. If the distribution of quantitative variables was skewed, log-transformed values were used for the analysis. Association between categorical variables was tested by the chi-square test for contingency tables. Frequencies of genotypes/alleles were determined by the gene counting method. Analyses were conducted with the SPSS (version 11.1) software package.

RESULTS {#sec1-4}
=======

According demographic and clinical data of stroke patients and controls, we found that stroke patients were more often female, smokers, and hypertensive compared with controls. ACE genotypes and allele distribution among cases and controls were also determined and presented in [Table 1](#table001){ref-type="table"}. There was no significant difference in the distribution of ACE gene variant between cases and controls.

[Table 2](#table002){ref-type="table"} shows the ACE genotype and allele distribution among patients with large vessel stroke and small vessel (lacunar) stroke. Patients with D allele had 9.21 (95% CI 1.67--50.96) times higher risk for large vessel disease than lacunar stroke. Patients with D allel had 4,68 (95% CI 1.10--19.86) times higher risk for large vessel stroke than healthy persons D allele possessors.

Patients-carriers of DD genotypes had significantly higher (p\<0,05) tryglicerides, apolipoprotein B, higher ACE catalitic activity, and significantly lower (p\<0,05) HDL-choleterol and apolipoprotein AI concentrations compared with control group. Patients with IS had higher levels of systolic blood pressure, diastolic blood pressure, mean arterial pressure and pulse pressure regardless of ACE genotype they possess. There was no significant difference in serum lipids, apolipoproteins and blood pressure levels according ACE genotype in stroke patients group. Patients with DD genotype had significantly higher catalitic ACE activity than patients with II or ID genotype. ([Table 3](#table003){ref-type="table"})

DISCUSSION {#sec1-5}
==========

This is the first study in Serbia that has examined the effect of ACE I/D gene polymorphism on IS risk. No significant evidence was provided to support our hypothesis that ACE gene polymorphism may represent a susceptibility mutation for IS. Previous reports on ACE gene polymorphism and IS produced conflicting results as to the importance of ACE alleles in predisposition to IS. We compiled results from 7 meta-analyses and 53 case-control studies ([Table 4](#table004){ref-type="table"}).

The first meta-analysis has evaluated the risk of stroke in 1196 subjects versus 722 controls from seven studies. It was concluded that the ACE genotype conferred a small but modest effect, with an odds ratio of 1.31 (95% CI 1.06--1.62), according to a dominant model of inheritance. A weaker association was seen under a recessive model ([@ref57]). In a meta-analysis of Casas et al. ([@ref58]) including 2990 predominantly white patients and 11 305 controls, the DD genotype was shown to confer a small but significant risk of ischemic stroke (odds ratio 1.21; 95% CI 1.08--1.35). From 2007-2009 five meta-analysis were published. Ariyaratnam et al. ([@ref59]) investigated the association of *ACE* I/D in three ethnic groups of non-European descent (a total of 3572 Chinese individuals, 1601 Japanese individuals, and 2750 Korean individuals). The overall OR for the nine studies in the Chinese population was 1.90 (95% CI 1.23--2.93) and for six Japanese studies the OR was 1.74 (95% CI 0.88--3.42). The overall OR in the Asian group (Chinese and Japanese) was 1.82 (95% CI 1.28--2.60). Meta-analysis of Banerjee et al. ([@ref60]) included six studies and did not detect a significant association with ACE gene insertion/deletion polymorphism. Xu et al. ([@ref61]) identified statistically significant associations with IS and ACE I/D (OR = 1.87, 95% CI =1.45--2.42 (15 studies, 1935 patients/1485 controls). Tao i sar. ([@ref62]) analyzed 29 studies in Chinese population (3654 patients/3058 controls) and found that ACE DD genotype is a risk factor cerebral infarction in Chinese population (OR 1,91 (95% CI 1,56--2,34), P\<0,00001). Rao et al. ([@ref63]) investigated the association of IS subtypes of subjects with the ACE I/D polymorphism published in 11 papers and gave ACE/DD OR 1.31 for small vessel stroke (95% CI 0.96--1.79, p = 0.09) compared to large vessel stroke (OR 1.02, 95% CI 0.82--1.26, p = 0.88) showed a preferential association for the DD genotype with small compared to large vessel disease.

Twenty three out of 53 studies ([Table 4](#table004){ref-type="table"}) examined the association of ACE gene polymorphism and ischemic stroke yielded a significant association with IS. Only a few studies have been done on the association of the ACE I/D polymorphism with lacunar infarction. Markus et al. ([@ref7]) studied this polymorphism in a small series of lacunar infarction cases (n=18) in which there was a positive association between D alele and lacunar infarction; OR associated with the DD genotype for lacunar stroke was 5.60 (95% CI, 2.00 to 15.71). Study on a Japanese population found that, in hypertensive patients only, the ACE D allele was associated with silent brain infarction ([@ref11]). However, this result was not replicated in another study using a larger population of lacunar infarction patients (n=130) ([@ref9]). Watanabe et al. ([@ref18]) showed no association of the ACE polymorphism with SBI in a smaller population (n=36). Takami et al. ([@ref64]) failed to show an association with number of lacunae in 134 Japanese patients.

Discrepancy in the obtained results can be explained by heterogeneity of study designs employed, differences in inclusion and exclusion criteria, ethnically different patient populations, small sample sizes, unmatched controls, combinations of ischemic and hemorrhagic strokes, different stroke subtypes and age of stroke onset, type of statistical evaluation, covariates, correction for multiple testing, and other factors that affect many publications.

There is less literature data about the association of serum lipids and apolipoproteins with ACE *I/D* polymorphism in patients with IS. The results of our study are consistent with two previously published studies. Del Ser et al. ([@ref65]) showed that serym triglycerides concentration is elevated in stroke patients with *DD* ACE genotype. Sertić et al. ([@ref14]) found significant association of triglycerides concentration and *DD* genotype (DD\>ID=II). It can be hypothesized that the increased serum triglycerides level in *DD* ACE genotype could be a feature of an insulin resistence syndrome and determine atherogenic and thrombogenic risk ([@ref65]).

Agerholm-Larsen et al. ([@ref66]) determined the effect of *ACE* genotype on serum ACE activity in 900 women and men from the Copenhagen City Heart Study and found that ACE gene polymorphism explains 30-40% of variability in serum ACE activity and this effect was codominant, with *DD* subjects having the highest, *ID* subjects intermediate, and *II* subjects the lowest serum ACE activity. The relatively small number of published studies with contradictory results examined the association between ACE activity and ACE I/D polymorphism in patients with IS compared to the number of studies that examined only the association of ACE I/D polymorphism polymorphism with IS.

Our study showed expected trend in ACE activity (DD\>ID\>II) in patient and control groups. Patients with DD genotype had significantly higher ACE activity (p\<0,05) compared with controls. This result is in accordance with croatian study (patients with angiographicaly proved cerebral atherosclerosis) ([@ref14]). Dikmen et al. ([@ref46]) examined Turkish acute stroke patients (185) although ACE activity was high in DD genotype, no difference was determined to ACE enzyme activity according to ACE genotypes in patients and controls. Some studies suggested that D allele of the ACE gene is a marker of an elevated circulation ACE level**.** Catto et al. ([@ref9]) reported plasma ACE activity significantly lower in stroke patients (cerebral infarction or cerebral hemorrhage) than in controls, and levels of ACE activity were significantly lower during the acute phase of stroke but were similar to level of control activity after 3 months. Markus et al. ([@ref7]) found that patients with IS and DD genotype has higher ACE activity compared with carriers of II genotype.

We expect that subsequent genome-wide association studies in large and well-characterized groups of patients of different ethnic origin will contribute substantially in the near future to a better understanding of the pathophysiology underlying ischemic stroke and permit the identification of new therapeutic targets aimed at stroke prevention and neuroprotection from ischemic injury.
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###### 

GENOTYPE AND ALLELE FREQUENCIES OF ACE IN SERBIAN STROKE PATIENTS AND CONTROL SUBJECTS.

  ACE                       Stroke patients   Control subjects                  
  ------------------ ------ ----------------- ------------------ -------------- --------------
  Genotypes          *II*   8                 (0,123 )           59             **(0,179 )**
  *ID*               37     (0,569 )          168                **(0,509 )**   
  *DD*               20     (0,308 )          103                **(0,312 )**   
  Allele frequency   *I*    52                (0.400)            286            **(0.433)**
  *D*                78     (0.600)           374                **(0.567)**    

###### 

Genotype and Allele frequencies of ACE in subgroups of IS patients.

  ACE                Genotip ACE   Large vessel IS   Lacunar stroke                 
  ------------------ ------------- ----------------- ---------------- ------------- -------------
  Genotypes          *II*          2                 (0,044)          6             **(0,300)**
  *ID*               28            (0,600)           9                **(0,500)**   
  *DD*               15            (0,356)           5                **(0,200)**   
  Allele frequency   *I*           32                (0,344)          21            **(0,550)**
  *D*                58            (0,656)           19               **(0,450)**   

###### 

LIPID PROFILE, BP LEVELS AND ACE ACTIVITY IN RELATION TO ACE GENOTYPE IN IS PATIENTS AND CONTROLS.

                                    ACE genotype   Stroke patients   Control subjects   p, Student t-test            
  --------------------------------- -------------- ----------------- ------------------ ------------------- -------- --------
  Total cholesterol (mmol/L)        *II*           5,10              0,96               5,77                1,32     \>0,05
  *ID*                              6,00           1,31              5,77               1,15                \>0,05   
  *DD*                              6,60           1,86              5,76               1,36                \>0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  HDL-choleterol (mmol/L)           *II*           1,08              0,30               1,37                0,37     \<0,05
  *ID*                              1,18           0,55              1,38               0,36                \<0,05   
  *DD*                              1,10           0,52              1,45               0,39                \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  LDL-cholesterol (mmol/L)          *II*           3,07              0,91               3,81                1,11     \>0,05
  *ID*                              3,61           1,41              3,75               1,00                \>0,05   
  *DD*                              4,00           1,81              3,66               1,17                \>0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Triglycerides (mmol/L)            *II*           1,76              0,83               1,31                0,86     \>0,05
  *ID*                              2,11           0,92              1,39               0,81                \<0,05   
  *DD*                              2,08           0,89              1,43               0,80                \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Apolipoprotein AI (g/L)           *II*           1,35              0,27               1,51                0,35     \>0,05
  *ID*                              1,33           0,35              1,47               0,33                \>0,05   
  *DD*                              1,31           0,40              1,53               0,30                \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Apolipoprotein B (g/L)            *II*           1,25              0,31               1,09                0,39     \>0,05
  *ID*                              1,40           0,55              1,19               0,42                \<0,05   
  *DD*                              1,57           0,67              1,02               0,29                \<0,05   
  p (ANOVA)                                        \>0,05            \<0,05                                          
  Apolipoprotein E (g/L)            *II*           53,30             10,12              41,45               20,18    \>0,05
  *ID*                              40,13          11,83             39,77              19,52               \>0,05   
  *DD*                              51,12          23,75             44,68              22,04               \>0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Lipoprotein (a) (g/L)             *II*           0,25              0,22               0,18                0,16     \>0,05
  *ID*                              0,26           0,42              0,22               0,26                \>0,05   
  *DD*                              0,17           0,16              0,19               0,13                \>0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  ACE (U/L)                         *II*           18,83             10,91              18,78               6,59     \>0,05
  *ID*                              38,81          11,78             35,28              12.29               \>0,05   
  *DD*                              67,95          20,21             57,40              13,25               \<0,05   
  p (ANOVA)                                        \<0,05            \<0,05                                          
  Systolic blood pressure (mmHg)    *II*           149,38            21,95              126,27              22,30    \<0,05
  *ID*                              164,32         29,93             128,54             20,48               \<0,05   
  *DD*                              160,00         31,50             131,41             23,14               \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Diastolic blood pressure (mmHg)   *II*           96,88             15,34              81,10               12,83    \<0,05
  *ID*                              97,30          13,57             81,49              11,06               \<0,05   
  *DD*                              96,50          16,23             83,33              12,26               \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Mean arterial pressure (mmHg)     *II*           114,37            16,08              96,16               15,29    \<0,05
  *ID*                              119,64         18,26             97,17              13,47               \<0,05   
  *DD*                              117,67         20,97             99,36              14,85               \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          
  Pulse pressure (mmHg)             *II*           52,50             16,26              45,17               13,71    \>0,05
  *ID*                              67,03          19,91             47,05              13,40               \<0,05   
  *DD*                              63,50          17,33             48,08              16,19               \<0,05   
  p (ANOVA)                                        \>0,05            \>0,05                                          

###### 

Genetic association studies of ACE I/D polymorphism and ischemic stroke.

  Study                               Year   Methodology                                        Phenotype                                                               Result
  ----------------------------------- ------ -------------------------------------------------- ----------------------------------------------------------------------- -------------------------
  Sharma i sar. ([@ref4])             1994   Case--control: 100 patients, 73 controls           IS                                                                      Negative
  Castellano i sar. ([@ref5])         1995   Cross-sectional: 199 patients                      IMT                                                                     Positive
  Dessi-Fulgheri i sar.([@ref6])      1995   Case--control: 193 patients, 147 controls          IS                                                                      
  Markus i sar. ([@ref7])             1995   Case--control: 100 patients, 137 controls          IS                                                                      Positive
  Ueda i sar. ([@ref8])               1995   Case--control: 488 patients, 188 controls          IS                                                                      Negative
  Catto i sar. ([@ref9])              1996   Case--control: 418 patients, 231 controls          IS                                                                      Negative
  Hosoi i sar. ([@ref10])             1996   Cross-sectional: 288 patients                      IMT NIDDM                                                               Positive
  Kario i sar. ([@ref11])             1996   Case--control: 138/90 patients, 90/104 controls    IS, lacunar stroke in hypertensive. Hypertensive/normotensive control   Positive
  Margaglione i sar. ([@ref12])       1996   Case--control: 101 pacijent, 109 controls          IS                                                                      Positive
  Pullicino i sar. ([@ref13])         1996   Case--control: 60 patients, controls               Lacunar stroke                                                          Negative
  Sertic i sar. ([@ref14])            1996   Case--control: 50 patients, 25 controls            CS                                                                      Negative
  Agerholm-Larsen i sar. ([@ref15])   1997   Case--referent: 184 pacijent, 5028 referenata      IS                                                                      Negative
  Agerholm-Larsen i sar. ([@ref15])   1997   Case--referent: 268 patients, 4015 referenata      IS                                                                      Negative
  Doi i sar. ([@ref16])               1997   Case--control: 181 patients, 271 controls          IS                                                                      Positive
  Nakata i sar. ([@ref17])            1997   Case--control: 55 patients, 61 controls            IS                                                                      Positive
  Watanabe i sar. ([@ref18])          1997   Cross-sectional: 169 patients                      CS/ lacunar stroke                                                      Positive
  Aalto Setala i sar. ([@ref19])      1998   Cross-sectional: 234 patients                      IS                                                                      Negative
  Molyaka i sar. ([@ref20])           1998   Case--control: 52 patients, 80 controls            IS                                                                      Negative
  Pfohl i sar. ([@ref21])             1998   Case--control: 388 patients                        IS                                                                      Negative
  Seino i sar. ([@ref22])             1998   Case--control: 26 patients, 28 controls            IS                                                                      Positive
  Shen i sar. ([@ref23])              1998   Case--control: 44 patients, 62 controls            IS                                                                      Positive
  Xu i sar. ([@ref24])                1998   Case--control: 65 patients, 117 controls           IS                                                                      Positive
  Heijmans i sar. ([@ref25])          1999   Cross-sectional: 79 patients                       CVD                                                                     Negative
  Kostulas i sar. ([@ref26])          1999   Case--control: 100 patients, 100 controls          IS/CS                                                                   Negative
  Notsu i sar. ([@ref27])             1999   Case--control: 175 patients, 213 controls          IS                                                                      Negative
  Zee i sar. ([@ref28])               1999   Nested case--control: 348 patients, 348 controls   IS/PICH                                                                 Negative
  Lin i sar. ([@ref29])               2000   Case--control: 306 patients, 300 controls          IS                                                                      Negative
  Wei i sar. ([@ref30])               2000   Case--control: 87 patients, 257 controls           IS                                                                      Positive
  Szolnoki i sar. ([@ref31])          2001   Case--control: 664 patients, 199 controls          IS                                                                      Negative
                                                                                                                                                                        Positive (small vessel)
  Um i sar. ([@ref32])                2001   Case--control: 106 patients, 498 controls          IS                                                                      Negative
  Zhang i sar. ([@ref33])             2001   Case--control: 152 patients, 72 controls           IS                                                                      Positive
  Zhang i sar. ([@ref34])             2001   Case--control: 165 patients, 106 controls          IS                                                                      Positive
  Li i sar. ([@ref35])                2002   Case--control: 143 patients, 154 controls          IS                                                                      Negative
  Ohkubo i sar. ([@ref36])            2002   Case--control: 69 patients, 294 controls           IS                                                                      Positive
  Szolnoki i sar. ([@ref37])          2002   Case--control: 292 patients, 652 controls          IS, large vessel                                                        Negative
                                             Case--control: 211 patients, 652 controls          IS, small vessel                                                        Positive
                                             Case--control: 186 patients, 652 controls          IS, mzxed type                                                          Negative
  Thomas i sar. ([@ref38])            2003   Case--control: 218 patients, 490 controls          IS                                                                      Negative
  Um i sar. ([@ref39])                2003   Case--control: 365 patients, 319 controls          IS                                                                      Negative
  Yuan i sar. ([@ref40])              2003   Case--control: 122 patients, 1229 controls         IS                                                                      Negative
  Karagiannis i sar. ([@ref41])       2004   Case--control: 100 patients, 100 controls          IS                                                                      Negative
  Wang i sar. ([@ref42])              2004   Case--control: 46 patients, 43 controls            IS                                                                      Positive
  Zee i sar. ([@ref43])               2004   Case--control: 319 patients, 2092 controls         IS                                                                      Negative
  Szolnoki i sar. ([@ref44])          2005   Case--control: 407 patients, 295 controls          IS                                                                      Negative
  Um i sar. ([@ref45])                2005   Case--control: 211 patients, 319 controls          IS                                                                      Positive
  Dikmen i sar. ([@ref46])            2006   Case--control: 185 patients, 50 controls           IS                                                                      Negative
  Gao i sar. ([@ref47])               2006   Case--control: 100 patients, 100 controls          IS                                                                      Negative
  Pera i sar. ([@ref48])              2006   Case--control: 368 patients, 456 controls          IS                                                                      Negative
  Szolnoki i sar. ([@ref49])          2006   Case--control: 272 patients, 308 controls          IS                                                                      Positive
  Tuncer i sar. ([@ref50])            2006   Case--control: 108 patients, 79 controls           IS                                                                      Negative
  Lalouschek i sar. ([@ref51])        2007   Case--control: 450 patients, 817 controls          IS/TIA                                                                  Negative
  Li i sar. ([@ref52])                2007   Case--control: 454 patients, 334 controls          IS                                                                      Positive
  Munchi i sar. ([@ref53])            2008   Case--control: 162 patients, 150 controls          IS                                                                      Positive
  Hong i sar. ([@ref54])              2008   Case--control: 232 patients, 225 controls          IS                                                                      Positive
  Celiker i sar. ([@ref55])           2008   Case--control: 162 patients, controls              IS                                                                      Positive
  Saidi i sar. ([@ref56])             2009   Case--control: 228 patients, 323 controls          IS                                                                      Negative
